Abstract | INTRODUCTION: AREAS COVERED: This article reviews the role of fenofibric acid in the context of results from recent randomized trials on fenofibrate, including the ACCORD Trial. It discusses the current status of fenofibric acid in the management of dyslipidemia, especially in combination with statins, and also addresses the comparative efficacy and safety profile of this new molecule against other agents in its class. EXPERT OPINION:
Fenofibric acid in combination with low- to moderate-dose statins is an effective and safe option in the treatment of mixed dyslipidemia, although the long-term effects on cardiovascular risk reduction need to be explored further.
|
Authors | Alok Saurav, Manu Kaushik, Syed M Mohiuddin |
Journal | Expert opinion on pharmacotherapy
(Expert Opin Pharmacother)
Vol. 13
Issue 5
Pg. 717-22
(Apr 2012)
ISSN: 1744-7666 [Electronic] England |
PMID | 22404421
(Publication Type: Journal Article, Review)
|
Chemical References |
- Hypolipidemic Agents
- fenofibric acid
- Fenofibrate
|
Topics |
- Fenofibrate
(analogs & derivatives, pharmacokinetics, therapeutic use)
- Humans
- Hyperlipidemias
(drug therapy, metabolism)
- Hypolipidemic Agents
(pharmacokinetics, therapeutic use)
|